Entropy Neurodynamics (ASX:ENP) Total Inventories: A$0.00 Mil (As of Dec. 2025)


What is Entropy Neurodynamics Total Inventories?

Entropy Neurodynamics ASX:ENP -3.23% Total Inventories is A$0.00 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Entropy Neurodynamics's total inventories for the quarter that ended in Dec. 2025 was A$0.00 Mil. Entropy Neurodynamics's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was A$0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Entropy Neurodynamics's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was A$0.00.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Entropy Neurodynamics  (ASX:ENP) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Entropy Neurodynamics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is

Net-Net Working Capital Per Share (Q: Dec. 2025 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(6.426+0.75 * 1.95+0.5 * 0-1.127
-0-0)/1609.510
=0.00

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Entropy Neurodynamics's Days Inventory for the six months ended in Dec. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2025 )/Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=0/0*365 / 2
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Entropy Neurodynamics's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2025 ) / Average Total Inventories (Q: Dec. 2025 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Entropy Neurodynamics's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Entropy Neurodynamics Total Inventories Related Terms

Entropy Neurodynamics Total Inventories Historical Data

* Premium members only.

The historical data trend for Entropy Neurodynamics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entropy Neurodynamics Total Inventories Chart

Entropy Neurodynamics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun25
Total Inventories
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Entropy Neurodynamics Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24 Jun25 Dec25
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entropy Neurodynamics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of A$0.00 Mil mean?
Entropy Neurodynamics (ASX:ENP) has a Total Inventories of A$0.00 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Entropy Neurodynamics and its competitors.
Is Entropy Neurodynamics' Total Inventories too high?
Entropy Neurodynamics' current Total Inventories is A$0.00 Mil.
How does Entropy Neurodynamics' Total Inventories compare to VRTX and REGN?
Entropy Neurodynamics' Total Inventories of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Entropy Neurodynamics and its competitors. Entropy Neurodynamics's current Total Inventories is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (ASX:ENP) is currently considered Fairly Valued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.03 — trading right at its estimated fair value. The current Total Inventories is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Entropy Neurodynamics (ASX:ENP), the current Total Inventories is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entropy Neurodynamics Business Description

Other Exchanges TYPTF:USA
Address 117 Camberwell Road,, Hawthorn East, Suite 1.01, Camberwell, Melbourne, VIC, AUS, 3123
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.